Last reviewed · How we verify
177Lu-PSMA-I&T
177Lu-PSMA-I&T is a radioligand therapy that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them.
177Lu-PSMA-I&T is a radioligand therapy that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation to kill them. Used for Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression.
At a glance
| Generic name | 177Lu-PSMA-I&T |
|---|---|
| Also known as | 177Lu-PNT2002 |
| Sponsor | Weill Medical College of Cornell University |
| Drug class | Radioligand therapy |
| Target | PSMA (prostate-specific membrane antigen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This drug combines a lutetium-177 radioisotope with a PSMA-targeting ligand that specifically recognizes and binds to PSMA expressed on prostate cancer cells. Once bound, the radioisotope delivers localized beta radiation directly to PSMA-positive tumors while sparing healthy tissue, enabling targeted internal radiation therapy for metastatic castration-resistant prostate cancer.
Approved indications
- Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression
Common side effects
- Hematologic toxicity (anemia, thrombocytopenia, leukopenia)
- Xerostomia (dry mouth)
- Nausea
- Fatigue
- Kidney toxicity
Key clinical trials
- Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients (PHASE2)
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (PHASE3)
- Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma (PHASE1)
- Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: (PHASE2)
- Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST) (PHASE2)
- PSMA Therapy and Immunotherapy in Kidney Cancer (PHASE1, PHASE2)
- 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer (PHASE3)
- Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 177Lu-PSMA-I&T CI brief — competitive landscape report
- 177Lu-PSMA-I&T updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI